Search | Clinical Trials Finder

Conditions: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions: Carboplatin, Endoscopic Biopsy, External Beam Radiation Therapy, Lenvatinib Mesylate, Paclitaxel, Pembrolizumab, Resection; Drug · Procedure · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Esophageal Cancer
Interventions: cisplatin, fluorouracil, Iressa, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Interventions: Active Surveillance With ctHPVDNA (NavDx®); Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Esophageal Cancer, Lung Cancer
Interventions: Interactive Voice Response System, Symptoms Report; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions: pazopanib hydrochloride, iodine I 131; Drug · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Thyroid Cancer
Interventions: patient interviews, CITSAV survey; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy; Biological · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Tadalafil, Placebo; Drug · Other
Lead sponsor: Donald T. Weed; Other
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Interventions: Radiation Therapy; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Esophageal Cancer
Interventions: cisplatin, gefitinib, paclitaxel, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Esophageal Cancer, Lung Cancer
Interventions: positron emission tomography, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Cancer
Interventions: bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Venous Thromboembolism, Head and Neck Cancer
Interventions: Enoxaparin, Apixaban; Drug
Lead sponsor: Kiranya Arnold; Other
Eligibility: 18 Years to 89 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Esophageal Cancer
Interventions: cetuximab, cisplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 74 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 173
States / cities: Tucson, Arizona • Auburn, California • Cameron Park, California + 140 more

Conditions: Oropharyngeal Cancer
Interventions: TORS, Adjuvant Radiation Therapy; Procedure · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease
Interventions: High flow humidification, Conventional cool mist aerosol humidification; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Oral Cancer
Interventions: Oral Cavity Reconstruction; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery, WEE1 Inhibitor AZD1775; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Cancer
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Cancers
Interventions: Atorvastatin, Fish Oil Supplement, Placebo; Drug · Dietary Supplement · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Medpulser electroporation with Bleomycin, Tumor surgical excision; Combination Product · Procedure
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
Interventions: Lidocaine 1% Injectable Solution; Drug
Lead sponsor: Ryan Carey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Tumor Resection; Procedure · Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Search by objective public record fields.

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Measuring Patient Expectations for Thyroid Surgery

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

High Flow vs Conventional Oxygen in Head and Neck Surgery

Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

TEST: Registry for Endoscopic Head and Neck Surgery

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer